AdaptSmartIMI

#MAPPs can be used to make much needed new drugs available earlier that make a difference to patients’ lives. Many can’t wait for drugs to come out in 5 or 6 years’ time. MAPPs can achieve this without compromising the evidence standards!! bit.ly/2przS3P

Education and communication are important too, and so is patient involvement #adaptivepathways @eupatientsforum @eurordis

ADAPT SMART recommendations by @SolangeRohou #adaptivepathways #Sustainability

Let’s face it, if you think of MAPPs as the intelligent combination of building blocks, then many of these building blocks are no longer controversial said Hans-Georg Eichler bit.ly/2przS3P @EMA_News #adaptivepathways #Sustainability

The ADAPT SMART infographic is live on adaptsmart.eu it’s a practical guide to help the various stakeholders navigate the website. Goal is to make all the information we developed available and to keep it alive for a number of years! #adaptivepathways #sustainability

#MAPPs is not a new designation, nor is it a new type of marketing authorisation. MAPPs seek to operate within the existing legal and regulatory frameworks #adaptivepathways @CASMIorg

There is still a lot to understand about practical applications of #MAPPs outside of the countries involved in @AdaptSmartIMI. We need to address the constraints in the context of the societal issues locally. bit.ly/2HR07sb #adaptivepathways @CASMIorg

When @beuc raised concerns about #MAPPs , we were said to be conservatives&not forward-looking. bit.ly/295bZVw Interestingly enough, after 2years of project, @AdaptSmartIMI highlights the same problematic. @EMA_News @EU_Health twitter.com/IMI_JU/status/…

Fascinating new pathway analysis for a theoretical #MAPPs product. @AdaptSmartIMI

Changing process is difficult, as some payers think #MAPPs is too hard politically, too complicated, or too time consuming. However, the reality is that we have to think about new ways to handle our work @ad_schuurman @ZiNLActueel bit.ly/2IFgOrt #adaptivepathways

Putting stakeholders at the centre of decision-making is a key concept of the #MAPPs approach, it offers a huge potential benefit over a more traditional drug development paradigm #adaptivepathways @JacolineBouvy @NICESciAdvice bit.ly/2FOOViW

Hans-Georg Eichler of @EMA_News discusses the why, how and when of #MAPPs at @AdaptSmartIMI closing meeting #adaptivepathways

The @AdaptSmartIMI consortium created six framework questions that need to be addressed at key decision moments in time, the beta thalassemia case study addresses the insights and questions raised by the #MAPPs pathway #adaptivepathways

.@MIT NEWDIGS will present a case study of several of the findings of the #MAPPs project, highlighting the key decision moments that occur in the evaluation of a MAPPs product #adaptivepathways

All the stakeholders around the table for a lively panel debate moderated by @DuaneSchulthess. Thanks @wim_werk @SolangeRohou @ValeStrammi @EMA_News @ad_schuurman & Bojan! #adaptivepathways

How does @SolangeRohou see the future of #adaptivepathways?

The ADAPT SMART ‘wish list’ was quite realistic since all what was planned was delivered says @SolangeRohou #adaptivepathways

Today it's the @AdaptSmartIMI closing meeting in Budapest, and our @ValeStrammi is there to present the #patient perspective on #adaptivepathways.

.@wim_werk shares his personal reflections and experiences with ADAPT SMART and #MAPPs #adaptivepathways